National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Clinical Trial

Official title:

National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02664935
• Other study ID #: RG_14-072
• Secondary ID: 2014-000814-73IS
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 2015
• Est. completion date: September 2024

Study information

• Verified date: May 2024
• Source: University of Birmingham
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.

Description:

The trial is primarily an enrichment putative biomarker design, including patients who are positive for at least one of the actionable targets included in the trial. Patients who are positive for just one putative biomarker will receive the experimental targeted drug specific for that putative biomarker. Putative biomarkers within each drug cohort have been chosen such that in the majority of cases it is not expected that patients will be positive for two or more putative biomarkers within the same drug. In the rare situation that patients are positive for two or more putative biomarkers relevant across different drugs, treatment will be allocated in accordance with the following strategy:

• All amplifications and rearrangements will be treated with targeted agent appropriate to them irrespective of concomitant mutations. This will yield crucial predictive biomarker information.

• For concomitant mutations decisions will be made by the Chief Investigator on a case-by-case basis and based on close consideration of pathway preference and likely dominance of one signal pathway over another together with any pre-clinical efficacy studies that address the activity of the drugs in the presence of concomitant mutations. A trumping strategy has been devised for this purpose.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 423
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Core inclusion and exclusion criteria are presented below. Additional inclusion/exclusion criteria apply to each arm and are presented in the relevant arm supplements of the protocol.

Inclusion Criteria:

• Prior anti-cancer treatment:

• Patients who refuse any standard of care first line therapy, are eligible to receive National Lung Matrix Trial treatment as first line therapy, providing they explicitly consent to this effect.

• Patients who have previously consented to and received standard of care first line therapy must have completed all standard of care therapy that the treating oncologist thinks is appropriate. As a minimum patients must have failed one or more lines of treatment (either radiological documentation of disease progression or due to toxicity). Patients whose disease has increased in size but is not classed as progressive disease as per RECIST criteria, will be eligible. Patients with no change at all in dimension of disease (i.e. true stability) after first line therapy will not be eligible.

• Patients who have progressed after surgical resection and adjuvant therapy will be eligible for entry without the need for the administration of first line metastatic therapy.

• Patients will also be eligible without the necessity for first line regimen if they have relapsed within 6 months of completion of definitive chemoradiation.

• Consented and provided an adequate specimen to adequately characterise the molecular genotype of the tumour in the molecular pre-screening according to the molecular exclusion rules (see Section 6.4 for definition of an adequate sample).

• Histological or cytologically confirmed NSCLC stage III (not suitable for radical radiotherapy or surgery) or stage IV. This includes patients who may have abnormal histology, but IHC strongly support either squamous cell carcinoma (p63 positivity) or adenocarcinoma (Thyroid transcription factor 1 [TTF1] positivity). If a physician and pathologist are convinced after multi-disciplinary review that the patient has stage III or IV NSCLC but where all the IHC is negative and the morphology does not distinguish a specific sub-type, these patients will be eligible for non-histology specific cohorts.

• CT or MRI scan of head, chest and abdomen within 28 days of treatment demonstrating measurable disease as per RECIST version 1.1 (see Appendix 1: Response Evaluation Criteria in Solid Tumours Version 1.1). (The same imaging modality must be used throughout treatment).

• Adequate haematological function within 7 days of treatment.

• Haemoglobin = 90 g/L.

• Absolute neutrophil count (ANC) = 1.5 x 109/L.

• Platelets = 100 x 109/L.

• Adequate hepatic function within 7 days of treatment in patients with no liver metastasis (see arm specific entry criteria for adequate hepatic function in patients with liver metastases).

• Total serum bilirubin = 1.5 x upper limit of normal (ULN). (Note that this will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of haemolysis or hepatic pathology), who may be allowed inclusion at the discretion of the local Investigator).

• Alanine transferase (ALT) = 2.5 x ULN.

• Aspartate transferase (AST) = 2.5 x ULN.

• Adequate renal function within 7 days of treatment.

• Creatinine clearance (CLcr) >50 ml/min (measured or calculated by Cockcroft and Gault equation - see Appendix 4: Cockcroft Gault Formula - Creatinine Clearance). If calculated CLcr is <50 ml/min a direct measurement of glomerular filtration rate (GFR) such as EDTA may be performed. If the value is >50 ml/min the patient is eligible.

• Age = 18 years.

• Females must agree to use adequate contraceptive measures (as defined in Section 6.3), should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:

• Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments

• Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

• Women aged under 50 years old would be consider postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range for the institution.

• Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.

Exclusion Criteria:

• Major surgery (excluding placement of vascular access) within 4 weeks prior to treatment.

• Nausea, vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease) that would preclude adequate absorption.

• Any psychological, familial, sociological or geographical condition hampering protocol compliance.

• Concurrent malignancies or invasive cancers diagnosed within past 3 years except for adequately treated basal cell carcinoma of the skin and in situ carcinoma of the uterine cervix.

• Judgement by the local Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

• Any unresolved toxicity of grade 2, 3 or 4 from previous treatment (excluding alopecia) at Registration (see CTCAE - Appendix 3: Common Toxicity Criteria Gradings).

• Patients who have previous symptomatic brain metastases or spinal cord compression are excluded unless they have had adequate treatment, no evidence of progression or symptoms, and have had no requirement for steroid treatment in the previous 28 days before commencement of trial treatment.

• Patients with asymptomatic brain metastases picked up at screening CT scan are not excluded providing that in the view of the local Investigator they do not require immediate radiotherapy or surgical intervention, and have had no requirement for steroid treatment in the previous 28 days before commencement of trial treatment.

• As judged by the local Investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus. Screening for chronic conditions is not required.

• Pregnant and lactating patients (patients of childbearing potential must have a negative pregnancy test prior to registration).

Cardiac exclusion criteria, performance status and prior treatment washout periods are detailed within the National Lung Matrix Trial arm-specific eligibility criteria.

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Squamous Cell
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Drug:
• AZD4547
FGFR Inhibitor
• Vistusertib
MTORC1/2 Inhibitor
• Palbociclib
CDK4/6 Inhibitor
• Crizotinib
ALK/MET/ROS1 Inhibitor
• Selumetinib
MEK Inhibitor
• Docetaxel
Taxane, anti-mitotic cytotoxic chemotherapy
• AZD5363
AKT Inhibitor
• Osimertinib
EGFRm+ T790M+ Inhibitor
• Durvalumab
Anti-PDL1
• Sitravatinib
VEGFR Inhibitor
• AZD6738
ATR inhibitor

Locations

Country	Name	City	State
United Kingdom	Aberdeen Royal Infirmary	Aberdeen
United Kingdom	Belfast City Hospital, Belfast Health and Social Care Trust	Belfast
United Kingdom	Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust	Birmingham
United Kingdom	Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust	Birmingham
United Kingdom	University Hospitals Bristol NHS Foundation Trust	Bristol
United Kingdom	Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust	Cambridge
United Kingdom	Velindre Cancer Centre, Velindre NHS Trust	Cardiff
United Kingdom	Colchester General Hospital	Colchester
United Kingdom	Edinburgh Cancer Centre, Western General Hospital	Edinburgh
United Kingdom	Royal Devon and Exeter Hospital	Exeter
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow
United Kingdom	St. James' University Hospital, Leeds Teaching Hospital NHS Trust	Leeds
United Kingdom	Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust	Leicester
United Kingdom	Charing Cross Hospital, Imperial College Healthcare NHS Trust	London
United Kingdom	Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust	London
United Kingdom	Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust	London
United Kingdom	St Bartholomew's Hospital, Barts Health NHS Trust	London
United Kingdom	University College Hospital, University College London Hospitals NHS Foundation Trust	London
United Kingdom	Maidstone Hospital	Maidstone
United Kingdom	The Christie Hospital, The Christie NHS Foundation Trust	Manchester
United Kingdom	Sir Bobby Robson Cancer Trial Research Centre, The Newcastle upon Tyne Hospitals	Newcastle
United Kingdom	Churchill Hospital, Oxford University Hospitals NHS Foundation Trust	Oxford
United Kingdom	Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust	Sheffield
United Kingdom	Southampton General Hospital, University Hospital Southampton NHS Foundation Trust	Southampton
United Kingdom	Clatterbridge Cancer Centre	Wirral

Sponsors (6)

Lead Sponsor	Collaborator
University of Birmingham	AstraZeneca, Cancer Research UK, Experimental Cancer Medicine Centres, Mirati Therapeutics Inc., Pfizer

Country where clinical trial is conducted

United Kingdom, 

References & Publications (2)

Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, Walker I, Carr TH, Wherton D, Billingham LJ. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Ann Oncol. 2015 Dec;26(12):2464-9. doi: 10.1093/annonc/mdv394. Epub 2015 Sep 25. — View Citation

Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response (OR)	CT scans every 6 weeks from baseline until disease progression (Primary outcome for all Trial Arms except Arm C). Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	From baseline until disease progression, assessed up to 18 months.
Primary	Progression-free survival time (PFS)	Defined as the time from commencement of trial treatment to the date of CT scan when progressive disease first recorded or date of death without previously recorded progression (Primary Outcome for Arm C only). Patients who are alive with no recorded progression at the time of analysis will be censored at the date of the CT scan when they were last recorded with an evaluable measure that was not progression. Investigators expect patients to participate in the study for a maximum of 18 months, however, cannot guarantee that some patients may participate over 18 months.	From date of commencement of trial treatment to date of CT scan when progressive disease first recorded or date of death without previously recorded progression, assessed up to 18 months.
Primary	Durable clinical benefit (DCB)	A patient will be defined as experiencing DCB if they remain free of disease progression at their fourth CT or MRI scan since treatment start date, i.e. approximately 24 weeks, or at any scan after 24 weeks that shows the patient free of disease progression (co-primary outcome for all Trial Arms except Arm C & G)	From baseline until the first scan after 24 weeks showing the patient free of disease progression.
Secondary	Best percentage change in sum of target lesion diameters (PCSD)	At each evaluation, the longest diameters of all selected target lesions will be measured and summed and the percentage change from the baseline measurement will be calculated. The best percentage change is the one that reflects either the greatest decrease or the least increase over the whole period of assessment. Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	From baseline until disease progression, assessed up to 18 months.
Secondary	Time to Progression (TTP)	This is defined as the time from commencement of trial treatment to the date of the CT scan when progressive disease first recorded. Patients with no recorded progression at the time of analysis or who die without recorded progression will be censored at the date of the CT scan when they were last recorded with an evaluable measure that was not progression. Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	The time from commencement of trial treatment to the date of the CT scan when progressive disease first recorded, assessed up to 18 months.
Secondary	Overall survival time (OS)	This is defined as the time of commencement of trial treatment to the date of death. Patients who are alive at the time of analysis will be censored at the date last seen alive. Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	From time of commencement of trial treatment until date of death, assessed up to 18 months.
Secondary	Adverse Events (AE)	Adverse events will be recorded in relation to each cycle of treatment and graded according to Common Terminology Criteria for Adverse Events (CTCAE). The incidence of each adverse event (all grades and grade 3/4) will be reported as a per-patient-cycle rate and as a per-patient rate. Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	From date of informed consent to trial treatment until 28 days after the last administration of the last treatment, assessed up to 18 months.

External Links

•   MA06. 06 A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J
•   PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC) Middleton, G. et al. Journal of Thoracic Oncology, Volume 14, Issue 10, S7